Clinical trial
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely…
NCT03524092 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT03524092 |
|---|---|
| Title | A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis |
| Official title | A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2) |
| Acronym | LUCENT 2 |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Mirikizumab SC, Mirikizumab IV, Placebo SC |
| Enrollment | 1,177 |
| Start date | Oct 19, 2018 |
| Primary completion | Nov 3, 2021 |
| Completion | Feb 17, 2025 |
| First posted | May 14, 2018 |
| Last update posted | Oct 14, 2025 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, India and 22 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: